Приказ основних података о документу

dc.creatorLazarević, Milica
dc.creatorJovanović, Nikola
dc.creatorCvetković, Vladimir J.
dc.creatorTošić, Svetlana
dc.creatorVitorović, Jelena
dc.creatorStamenković, Slaviša
dc.creatorNikolov, Vesna
dc.creatorVidović, Nataša
dc.creatorKostić Perić, Jelena
dc.creatorJovanović, Marija
dc.creatorMitrović, Tatjana
dc.date.accessioned2023-03-01T10:08:40Z
dc.date.available2023-03-01T10:08:40Z
dc.date.issued2023
dc.identifier.issn2075-4418
dc.identifier.urihttps://www.mdpi.com/2075-4418/13/3/360
dc.identifier.urihttps://imagine.imgge.bg.ac.rs/handle/123456789/1777
dc.description.abstractComparative analysis of the conventional methylation-specific PCR (MSP) vs. the quantitative MSP (qMSP) assessment of the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in 34 snap-frozen (SF) glioma samples was performed. The accuracy of the semi-quantitative MSP was compared with the corresponding qMSP semi-quantitative values using two semi-quantitative cut-off values (0—unmethylated and 1—weakly methylated) to discriminate methylated from unmethylated samples. In the case of the cut-off value 0, MSP test showed 80.0% sensitivity and 78.9% specificity compared to the reference qMSP analysis. However, when using the cut-off value 1, the diagnostic accuracy of the MSP test was significantly higher (85.7% sensitivity, 85.2% specificity). Fleiss’ Kappa statistical analyses indicated moderate agreement (Fleiss’ Kappa Coefficient = 0.509; 70.59% agreement) between MSP and qMSP semi-quantitative measurements of MGMT promoter methylation in glioma patients, justifying the conventional MSP use in diagnostics and confirming its high reliability. Further, we aimed to compare the validity of SF and formalin-fixed paraffin-embedded (FFPE) glioma samples for MGMT testing. Statistical analyses indicated moderate overall agreement of FFPE glioma samples and SF MSP semi-quantitative measurements (Fleiss’ Kappa Coefficient = 0.516/0.509; 70.0% agreement) and emphasized their low reliability in the assessment of highly methylated MGMT promoter samples.
dc.languageen
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200042/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200124/RS//
dc.relation.isversionofhttps://doi.org/10.3390/diagnostics13030360
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceDiagnostics
dc.sourceDiagnostics
dc.subjectMGMT
dc.subjectFFPE
dc.subjectglioma
dc.subjectMSP
dc.subjectprognostic factor
dc.subjectqMSP
dc.titleA Comparison of MGMT Testing by MSP and qMSP in Paired Snap-Frozen and Formalin-Fixed Paraffin-Embedded Gliomas
dc.typearticleen
dc.rights.licenseBY
dc.citation.issue3
dc.citation.rankM22~
dc.citation.spage360
dc.citation.volume13
dc.identifier.doi10.3390/diagnostics13030360
dc.identifier.fulltexthttps://imagine.imgge.bg.ac.rs/bitstream/id/98059/A_Comparison_of_MGMT_Testing_by_MSP_and_qMSP_in_Paired_Snap_Frozen_and_Formalin_Fixed_Paraffin_Embedded_Gliomas_2023.pdf
dc.identifier.scopus2-s2.0-85147883092
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу